Efficacy and Safety of 5-Day Oral Ensitrelvir for Patients With Mild to Moderate COVID-19: The SCORPIO-SR Randomized Clinical Trial

Efficacy and Safety of 5-Day Oral Ensitrelvir for Patients With Mild to Moderate COVID-19: The SCORPIO-SR Randomized Clinical Trial

Treatment options for COVID-19 are warranted irrespective of the presence of risk factors for severe disease. To assess the efficacy and safety of ensitrelvir in patients with mild to moderate COVID-19. This phase 3 part of a phase 2/3, double-blind, placebo-controlled randomized clinical trial was...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:JAMA network open 2024-02, Vol.7 (2), p.e2354991
Hauptverfasser: Yotsuyanagi, Hiroshi, Ohmagari, Norio, Doi, Yohei, Yamato, Masaya, Bac, Nguyen Hoang, Cha, Bong Ki, Imamura, Takumi, Sonoyama, Takuhiro, Ichihashi, Genki, Sanaki, Takao, Tsuge, Yuko, Uehara, Takeki, Mukae, Hiroshi
Format: Artikel
Sprache:eng
Schlagworte:
Adolescent
Adult
Aged
Antiviral drugs
Child
Clinical trials
COVID-19
Drugs, Chinese Herbal
Female
Humans
Indazoles
Infectious Diseases
Male
Middle Aged
Online Only
Original Investigation
Risk Factors
SARS-CoV-2
Triazines
Triazoles
Young Adult
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Treatment options for COVID-19 are warranted irrespective of the presence of risk factors for severe disease. To assess the efficacy and safety of ensitrelvir in patients with mild to moderate COVID-19. This phase 3 part of a phase 2/3, double-blind, placebo-controlled randomized clinical trial was conducted from February 10 to July 10, 2022, with a 28-day follow-up period, at 92 institutions in Japan, Vietnam, and South Korea. Patients (aged 12 to
ISSN:2574-3805
2574-3805
DOI:10.1001/jamanetworkopen.2023.54991